Terms ending in 2036
Every in-force patent on Immunocore Limited's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,124,556 | TCR Libraries In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 11,136,575 | TCR Libraries In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,792,333 | Peptides Derived from Actin-Like Protein 8 (ACTL8) In force · High confidence | Immunocore Limited | In force | High confidence | |
| US 10,980,893 | Peptides Derived from Transient Receptor Potential Cation Channel Subfamily M Member 1 (TRPM1), Complexes Comprising Such Peptides Bound to MHC Molecules In force · High confidence | Immunocore Limited | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.